Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer.
Phase of Trial: Phase I
Latest Information Update: 08 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 02 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.